Malignant melanoma

Dermatologic Surgery

Volumn 22, Issue 3, 1996, Pages 234-240

  Parker, Timothy ^a   Zitelli, John ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER STAGING; CLINICAL FEATURE; HUMAN; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS;

EID: 0029993693     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4725.1996.tb00314.x     Document Type: Article

References (24)

1. Brodland DG, Zitelli JA. Mechanisms of metastasis. J Am Acad Dermatol 1992;27:1-8.
2. Reintgen DS et al. Prognosis for recurrent stage I malignant melanoma. Arch Surg 1987;122:1338.
3. Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S Cutaneous melanoma, 2nd ed., Philadelphia, J.B. Lippincott Co., 1992.
4. McCarthy WH et al. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet 1988;166:497.
5. Williams PL, Warwick R. Grays Anatomy, 36th ed., Philadelphia: W.B. Saunders, 1980.
6. Handley WS. The pathology of melanocytic growths in relation to their operative treatment. Lancet 1907;365:927-33.
7. Olsen G. The malignant melanoma of the skin: new theories based on a study of 500 cases. Acta Chir Scan (Suppl) 1966;365:1-220.
8. Breslow A, Macht SD. Optimal size of resection margin for thin cutaneous melanoma. Surg Gynecol Obstet 1988;145:691-2.
9. Robinson JK. Margin control for lentigo maligna. J Am Acad Dermatol 1994;31:79-85.
10. Zitelli JA. Mohs micrographic surgery for melanoma. Dermatol Clin 1989;7:4:833-43.
11. Zitelli JA, Moy RL Abell E. The reliability of frozen sections in the evaluation of surgical margins for melanoma. J Am Acad Dermatol 1991;24:102-6.
12. Wick MR, Swanson PE, Rocamora A. Recognition of malignant melanoma by monoclonal antibody HMB-45. An immunohistochemical study of 200 paraffin-embedded cutaneous tumors. J Cutan Pathol 1988;15:201-7.
13. Balch CM, Soong SJ, Milton GW, et al. A comparison of prognos-tic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg 1982;196:677-84.
14. Milton GW, Shaw HM, McCarthy WH, et al.: Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients. Br J Surg 1982;69: 108-11.
15. Reintgen DS, Cox EB, McCarty KS Jr., et al.: Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann Surg 1983;198:379-85.
16. Singluff CL et al. Surgical management of regional lymph nodes in patients with melanoma: experience with 4682 patients. Ann Surg 1994;219:120-30.
17. Veronesi U, Adamus J, Bandiera DC. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982;49:2420-30
18. Sim FH, Taylor WF, Pritchard DJ, et al. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 1986;61:697-705.
19. Roses DF, Karp NS, Oratz R, et al. Survival with regional and distant metastases from cutaneous malignant melanoma. Surg Gynecol Obstet 1991;172:262-68.
20. Hoffman SJ, et al. Cutaneous malignant melanoma. Curr Prob Dermatol 1993;5:1-44.
21. McClay EF, et al. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 1989;63:1292-5.
22. Zitelli JA. Mohs surgery for melanoma in Mohs Micrographic Surgery. Mikhail GR 1991 Philadelphia: W.B. Saunders, 275-88.
23. Rogers GS, Kopf AW, Rigel DS, et al. Hazard-rate analysis in stage I malignant melanoma. Arch Derm 1986;122:999-1006.
24. Brown CD, Zitelli JA. The prognosis and treatment of true local cutaneous recurrent malignant melanoma. Dermatol Surg 1995; 21:285-90.